Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review

[1] Armstrong AW(2020)Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis JAMA Dermatol 156 258-269

[2] Puig L(2020)Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Cochrane Database Syst Rev 1 CD011535-1328

[3] Joshi A(2015)Phase 3 studies comparing brodalumab with ustekinumab in psoriasis N Engl J Med 373 1318-409

[4] Sbidian E(2015)Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial J Am Acad Dermatol 73 400-417

[5] Chaimani A(2017)Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial J Am Acad Dermatol 76 405-431

[6] Afach S(2017)Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial J Am Acad Dermatol 76 418-506

[7] Lebwohl M(2015)Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice J Dermatolog Treat 26 502-1307

[8] Strober B(2017)Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) Br J Dermatol 176 1297-869

[9] Menter A(2017)Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study J Eur Acad Dermatol Venereol 31 863-382

[10] Thaçi D(2012)Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy PLoS ONE 7 e33486-136

[1] Armstrong AW(2020)Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis JAMA Dermatol 156 258-269

[2] Puig L(2020)Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Cochrane Database Syst Rev 1 CD011535-1328

[3] Joshi A(2015)Phase 3 studies comparing brodalumab with ustekinumab in psoriasis N Engl J Med 373 1318-409

[4] Sbidian E(2015)Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial J Am Acad Dermatol 73 400-417

[5] Chaimani A(2017)Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial J Am Acad Dermatol 76 405-431

[6] Afach S(2017)Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial J Am Acad Dermatol 76 418-506

[7] Lebwohl M(2015)Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice J Dermatolog Treat 26 502-1307

[8] Strober B(2017)Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) Br J Dermatol 176 1297-869

[9] Menter A(2017)Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study J Eur Acad Dermatol Venereol 31 863-382

[10] Thaçi D(2012)Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy PLoS ONE 7 e33486-136